(Circulation. 1996;94:1690-1697.)
© 1996 American Heart Association, Inc.
Articles |
Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries
the Department of Cardiology, Thoraxcenter (Cardiovascular Research Institute COEUR), Erasmus University Rotterdam (W.J. van der G., H.M.M. van B., P.W.S.), Netherlands; the Cleveland (Ohio) Clinic and Foundation (A.M.L., S.G.E., E.J.T.); and the Mayo Clinic and Foundation (R.S.S., D.R.H.), Rochester, Minn.
Correspondence to Willem J. van der Giessen, MD, PhD, Department of Cardiology, Thoraxcenter, Bd 412, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, Netherlands.
Background With the thrombogenic tendency and permanent implant nature of metallic stents, synthetic polymers have been proposed as candidate materials for stents and local drug delivery designs. We investigated the biocompatibility of several synthetic polymers after experimental placement in the coronary artery.
Methods and Results Five different biodegradable polymers (polyglycolic acid/polylactic acid [PGLA], polycaprolactone [PCL], polyhydroxybutyrate valerate [PHBV], polyorthoester [POE], and polyethyleneoxide/polybutylene terephthalate [PEO/PBTP]) and three nonbiodegradable polymers (polyurethane [PUR], silicone [SIL], and polyethylene terephthalate [PETP]) were tested as strips deployed longitudinally across 90° of the circumferential surface of coil wire stents. Appropriately sized polymer-loaded stents were implanted in porcine coronary arteries of 2.5- to 3.0-mm diameter. Four weeks after implantation, stent patency was assessed by angiography followed by microscopic examination of the coronary arteries. The biodegradable PCL, PHBV, and POE and the nonbiodegradable PUR and SIL evoked extensive inflammatory responses and fibrocellular proliferation (thickness of tissue response: 0.79±0.22, 1.12±0.01, 2.36±0.60, 1.24±0.36, and 1.43±0.15 mm, respectively). Less but still severe responses were observed for the biodegradable PGLA and PEO/PBTP (0.46±0.18 and 0.61±0.23 mm, respectively) and for the nonbiodegradable PETP (0.46±0.11 mm).
Conclusions An array of both biodegradable and nonbiodegradable polymers has been demonstrated to induce a marked inflammatory reaction within the coronary artery with subsequent neointimal thickening, which was not expected on the basis of in vitro tests. The observed tissue response may be attributable to a combination of parent polymer compound, biodegradation products, and possibly implant geometry.
Key Words: stents • arteries • angioplasty • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur. Heart J., June 11, 2008; (2008) ehn253v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fishbein, I. Alferiev, M. Bakay, S. J. Stachelek, P. Sobolewski, M. Lai, H. Choi, I. -W. Chen, and R. J. Levy Local Delivery of Gene Vectors From Bare-Metal Stents by Use of a Biodegradable Synthetic Complex Inhibits In-Stent Restenosis in Rat Carotid Arteries Circulation, April 22, 2008; 117(16): 2096 - 2103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Aoki, A. Kirtane, M. B. Leon, and G. Dangas Coronary Artery Aneurysms After Drug-Eluting Stent Implantation J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 14 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Helmus, D. F. Gibbons, and D. Cebon Biocompatibility: Meeting a Key Functional Requirement of Next-Generation Medical Devices Toxicol Pathol, January 1, 2008; 36(1): 70 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Egashira, K. Nakano, K. Ohtani, K. Funakoshi, G. Zhao, Y. Ihara, J.-i. Koga, S. Kimura, R. Tominaga, and K. Sunagawa Local Delivery of Anti-Monocyte Chemoattractant Protein-1 by Gene-Eluting Stents Attenuates In-Stent Stenosis in Rabbits and Monkeys Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2563 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? Circulation, July 17, 2007; 116(3): 316 - 328. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Scheller, U. Speck, and M. Bohm Prevention of restenosis: is angioplasty the answer? Heart, May 1, 2007; 93(5): 539 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Khan, A. Agrotis, and A. Bobik Understanding the role of transforming growth factor-{beta}1 in intimal thickening after vascular injury Cardiovasc Res, May 1, 2007; 74(2): 223 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF]
|
|
|
|
|
|
K. Ohtani, K. Egashira, K. Nakano, G. Zhao, K. Funakoshi, Y. Ihara, S. Kimura, R. Tominaga, R. Morishita, and K. Sunagawa Stent-Based Local Delivery of Nuclear Factor-{kappa}B Decoy Attenuates In-Stent Restenosis in Hypercholesterolemic Rabbits Circulation, December 19, 2006; 114(25): 2773 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Scheller, C. Hehrlein, W. Bocksch, W. Rutsch, D. Haghi, U. Dietz, M. Bohm, and U. Speck Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter N. Engl. J. Med., November 16, 2006; 355(20): 2113 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R R Anis and K R Karsch The future of drug eluting stents Heart, May 1, 2006; 92(5): 585 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wessely, A. Schomig, and A. Kastrati Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar But Different J. Am. Coll. Cardiol., February 21, 2006; 47(4): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Lee, H.-C. Tan, and Y.-T. Lim Update on Drug-Eluting Stents for Prevention of Restenosis Asian Cardiovasc Thorac Ann, February 1, 2006; 14(1): 75 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Salu, J. M. Bosmans, Y. Huang, M. Hendriks, M. Verhoeven, A. Levels, S. Cooper, I. K. De Scheerder, C. J. Vrints, and H. Bult Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model Cardiovasc Res, February 1, 2006; 69(2): 536 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mehilli, A. Kastrati, R. Wessely, A. Dibra, J. Hausleiter, B. Jaschke, J. Dirschinger, A. Schomig, and for the Intracoronary Stenting and Angiographic Re Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss Circulation, January 17, 2006; 113(2): 273 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Azarbal and J. W. Currier Allergic Reactions After the Implantation of Drug-Eluting Stents: Is it the Pill or the Polymer? J. Am. Coll. Cardiol., January 3, 2006; 47(1): 182 - 183. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Nebeker, R. Virmani, C. L. Bennett, J. M. Hoffman, M. H. Samore, J. Alvarez, C. J. Davidson, J. M. McKoy, D. W. Raisch, B. K. Whisenant, et al. Hypersensitivity Cases Associated With Drug-Eluting Coronary Stents: A Review of Available Cases From the Research on Adverse Drug Events and Reports (RADAR) Project J. Am. Coll. Cardiol., January 3, 2006; 47(1): 175 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fishbein, I. S. Alferiev, O. Nyanguile, R. Gaster, J. M. Vohs, G. S. Wong, H. Felderman, I-W. Chen, H. Choi, R. L. Wilensky, et al. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents PNAS, January 3, 2006; 103(1): 159 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Q. Liu, P. K. Alkema, C. Tieche, B. J. Tefft, D. Z. Liu, Y. C. Li, B. E. Sumpio, J. A. Caprini, and M. Paniagua Negative Regulation of Monocyte Adhesion to Arterial Elastic Laminae by Signal Regulatory Protein {alpha} and Src Homology 2 Domain-containing Protein-Tyrosine Phosphatase-1 J. Biol. Chem., November 25, 2005; 280(47): 39294 - 39301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Karvouni, S Korovesis, and D G Katritsis Very late thrombosis after implantation of sirolimus eluting stent Heart, June 1, 2005; 91(6): e45 - e45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lansky, R. A. Costa, M. Mooney, M. G. Midei, H. K. Lui, W. Strickland, R. Mehran, M. B. Leon, M. E. Russell, S. G. Ellis, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1180 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sharif, K. Daly, J. Crowley, and T. O'Brien Current status of catheter- and stent-based gene therapy Cardiovasc Res, November 1, 2004; 64(2): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Schwartz, E. R. Edelman, For the Consensus Committee, A. Carter, N. A. Chronos, C. Rogers, K. A. Robinson, R. Waksman, L. Machan, J. Weinberger, et al. Preclinical Evaluation of Drug-Eluting Stents for Peripheral Applications: Recommendations From an Expert Consensus Group Circulation, October 19, 2004; 110(16): 2498 - 2505. [Full Text] [PDF]
|
|
|
|
|
|
B. Scheller, U. Speck, C. Abramjuk, U. Bernhardt, M. Bohm, and G. Nickenig Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis Circulation, August 17, 2004; 110(7): 810 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Vogt, A. Stein, G. Rettemeier, N. Krott, R. Hoffmann, J. v. Dahl, A.-K. Bosserhoff, W. Michaeli, P. Hanrath, C. Weber, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent Eur. Heart J., August 1, 2004; 25(15): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr How Many Grails Do We Need? Circulation, May 11, 2004; 109(18): 2158 - 2159. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lansky, R. A. Costa, G. S. Mintz, Y. Tsuchiya, M. Midei, D. A. Cox, C. O'Shaughnessy, R. A. Applegate, L. A. Cannon, M. Mooney, et al. Non-Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial Circulation, April 27, 2004; 109(16): 1948 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H Chong and J. W. Cheng Early Experiences and Clinical Implications of Drug-Eluting Stents: Part 1 Ann. Pharmacother., April 1, 2004; 38(4): 661 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Curcio, D. Torella, G. Cuda, C. Coppola, M. C. Faniello, F. Achille, V. G. Russo, M. Chiariello, and C. Indolfi Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H902 - H908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Virmani, G. Guagliumi, A. Farb, G. Musumeci, N. Grieco, T. Motta, L. Mihalcsik, M. Tespili, O. Valsecchi, and F. D. Kolodgie Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? Circulation, February 17, 2004; 109(6): 701 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr, M. B. Leon, J. W. Moses, J. J. Popma, D. Cutlip, P. J. Fitzgerald, C. Brown, T. Fischell, S. C. Wong, M. Midei, et al. Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis Circulation, February 10, 2004; 109(5): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gershlick, I. De Scheerder, B. Chevalier, A. Stephens-Lloyd, E. Camenzind, C. Vrints, N. Reifart, L. Missault, J.-J. Goy, J. A. Brinker, et al. Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial Circulation, February 3, 2004; 109(4): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Huang, K Salu, X Liu, S Li, L Wang, E Verbeken, J Bosmans, and I De Scheerder Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model Heart, February 1, 2004; 90(2): 195 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. S. Do, E. Y. Kao, F. Ganaha, H. Minamiguchi, K. Sugimoto, J. Lee, C. J. Elkins, P. G. Amabile, M. D. Kuo, D. S. Wang, et al. In-Stent Restenosis Limitation with Stent-based Controlled-Release Nitric Oxide: Initial Results in Rabbits Radiology, February 1, 2004; 230(2): 377 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Smith Why Coat a Stent with Polymer? Radiology, January 1, 2004; 230(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
|
|
K. Schurmann, J. Lahann, P. Niggemann, B. Klosterhalfen, J. Meyer, A. Kulisch, D. Klee, R. W. Gunther, and D. Vorwerk Biologic Response to Polymer-coated Stents: In Vitro Analysis and Results in an Iliac Artery Sheep Model Radiology, January 1, 2004; 230(1): 151 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Scheller, U. Speck, A. Schmitt, M. Bohm, and G. Nickenig Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1415 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Scheller, U. Speck, B. Romeike, A. Schmitt, M. Sovak, M. Bohm, and H.-P. Stoll Contrast media as carriers for local drug delivery: Successful inhibition of neointimal proliferation in the porcine coronary stent model Eur. Heart J., August 1, 2003; 24(15): 1462 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Heublein, R Rohde, V Kaese, M Niemeyer, W Hartung, and A Haverich Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart, June 1, 2003; 89(6): 651 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, P. W. Serruys, and M. A. Costa New Frontiers in Cardiology: Drug-Eluting Stents: Part I Circulation, May 6, 2003; 107(17): 2274 - 2279. [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Karnik, B. S. Brooke, A. Bayes-Genis, L. Sorensen, J. D. Wythe, R. S. Schwartz, M. T. Keating, and D. Y. Li A critical role for elastin signaling in vascular morphogenesis and disease Development, March 2, 2003; 130(2): 411 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Schwartz, E. R. Edelman, A. Carter, N. Chronos, C. Rogers, K. A. Robinson, R. Waksman, J. Weinberger, R. L. Wilensky, D. N. Jensen, et al. Drug-Eluting Stents in Preclinical Studies: Recommended Evaluation From a Consensus Group Circulation, October 1, 2002; 106(14): 1867 - 1873. [Full Text] [PDF]
|
|
|
|
|
|
M. Sturek and H. K. Reddy New tools for prevention of restenosis could decrease the 'oculo-stento' reflex Cardiovasc Res, February 1, 2002; 53(2): 292 - 293. [Full Text] [PDF]
|
|
|
|
|
|
H. C. Lowe, S. N. Oesterle, and L. M. Khachigian Coronary in-stent restenosis: Current status and future strategies J. Am. Coll. Cardiol., January 16, 2002; 39(2): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Peuster, P Wohlsein, M Brugmann, M Ehlerding, K Seidler, C Fink, H Brauer, A Fischer, and G Hausdorf A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal---results 6-18 months after implantation into New Zealand white rabbits Heart, November 1, 2001; 86(5): 563 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Teirstein Living the Dream of No Restenosis Circulation, October 23, 2001; 104(17): 1996 - 1998. [Full Text] [PDF]
|
|
|
|
|
|
I. Fishbein, M. Chorny, S. Banai, A. Levitzki, H. D. Danenberg, J. Gao, X. Chen, E. Moerman, I. Gati, V. Goldwasser, et al. Formulation and Delivery Mode Affect Disposition and Activity of Tyrphostin-Loaded Nanoparticles in the Rat Carotid Model Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1434 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Windecker, I. Mayer, G. De Pasquale, W. Maier, O. Dirsch, P. De Groot, Y.-P. Wu, G. Noll, B. Leskosek, B. Meier, et al. Stent Coating With Titanium-Nitride-Oxide for Reduction of Neointimal Hyperplasia Circulation, August 21, 2001; 104(8): 928 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Honda, E. Grube, L. M. de la Fuente, P. G. Yock, S. H. Stertzer, and P. J. Fitzgerald Novel Drug-Delivery Stent: Intravascular Ultrasound Observations From the First Human Experience With the QP2-Eluting Polymer Stent System Circulation, July 24, 2001; 104(4): 380 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Farb, P. F. Heller, S. Shroff, L. Cheng, F. D. Kolodgie, A. J. Carter, D. S. Scott, J. Froehlich, and R. Virmani Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent Circulation, July 24, 2001; 104(4): 473 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Heldman, L. Cheng, G. M. Jenkins, P. F. Heller, D.-W. Kim, M. Ware Jr, C. Nater, R. H. Hruban, B. Rezai, B. S. Abella, et al. Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis Circulation, May 8, 2001; 103(18): 2289 - 2295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, M. A. Costa, A. Abizaid, A. S. Abizaid, F. Feres, I. M. F. Pinto, A. C. Seixas, R. Staico, L. A. Mattos, A. G. M. R. Sousa, et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries : A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study Circulation, January 16, 2001; 103(2): 192 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Drachman, E. R. Edelman, P. Seifert, A. R. Groothuis, D. A. Bornstein, K. R. Kamath, M. Palasis, D. Yang, S. H. Nott, and C. Rogers Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2325 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hoffmann and G.S. Mintz Coronary in-stent restenosis--predictors, treatment and prevention Eur. Heart J., November 1, 2000; 21(21): 1739 - 1749. [PDF]
|
|
|
|
|
|
A. Colombo and E. Karvouni Biodegradable Stents : "Fulfilling the Mission and Stepping Away" Circulation, July 25, 2000; 102(4): 371 - 373. [Full Text] [PDF]
|
|